| Name | Cvs Pharmacy #10324 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 6420 Gaston Ave, Dallas, Texas 75214 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (469) 334-0758 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Mayo Clinic researchers have discovered the mechanisms behind two key checkpoints in cell growth and development - factors that may ultimately allow investigators to benchmark progression of tumor cells or stop them from further development.
An Ottawa Citizen article examines Canada-based charity WaterCan's projects in East Africa. "This year, WaterCan has worked with local African partners to retro-fit more than 50 schools [in] Uganda, Kenya, Ethiopia and Tanzania - and has just launched a major Christmas funding drive to expand their work in schools next year. In the past two years, the charity has spent more than $2 million on school and community water and sanitation projects," according to the article.
NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.
New research, by Dr. Sotirios Tsimikas of the University of California, San Diego, has produced the first convincing evidence that a type of fat in the bloodstream can trigger the earliest conditions that lead to clogged blood vessels, the highest cause of heart attacks.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
› Verified 7 days ago
| NPI Number | 1538575469 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY #10324 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 6420 Gaston Ave, Dallas, TX 75214 |
| Phone Number | 469-334-0758 |
News Archive
Mayo Clinic researchers have discovered the mechanisms behind two key checkpoints in cell growth and development - factors that may ultimately allow investigators to benchmark progression of tumor cells or stop them from further development.
An Ottawa Citizen article examines Canada-based charity WaterCan's projects in East Africa. "This year, WaterCan has worked with local African partners to retro-fit more than 50 schools [in] Uganda, Kenya, Ethiopia and Tanzania - and has just launched a major Christmas funding drive to expand their work in schools next year. In the past two years, the charity has spent more than $2 million on school and community water and sanitation projects," according to the article.
NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.
New research, by Dr. Sotirios Tsimikas of the University of California, San Diego, has produced the first convincing evidence that a type of fat in the bloodstream can trigger the earliest conditions that lead to clogged blood vessels, the highest cause of heart attacks.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
› Verified 7 days ago
News Archive
Mayo Clinic researchers have discovered the mechanisms behind two key checkpoints in cell growth and development - factors that may ultimately allow investigators to benchmark progression of tumor cells or stop them from further development.
An Ottawa Citizen article examines Canada-based charity WaterCan's projects in East Africa. "This year, WaterCan has worked with local African partners to retro-fit more than 50 schools [in] Uganda, Kenya, Ethiopia and Tanzania - and has just launched a major Christmas funding drive to expand their work in schools next year. In the past two years, the charity has spent more than $2 million on school and community water and sanitation projects," according to the article.
NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.
New research, by Dr. Sotirios Tsimikas of the University of California, San Diego, has produced the first convincing evidence that a type of fat in the bloodstream can trigger the earliest conditions that lead to clogged blood vessels, the highest cause of heart attacks.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
› Verified 7 days ago
Aerocare Home Medical Equipment, In Type: Durable Medical Equipment & Medical Supplies Supplier Location: 11130 Petal St, Dallas, Texas 75238 Phone: (214) 267-9000 | |
Aids Healthcare Foundation Type: Pharmacy Location: 2600 N Stemmons Fwy, Dallas, Texas 75207 Phone: (972) 584-9653 | |
Aids Healthcare Foundation Type: Community/Retail Pharmacy Location: 3920 Cedar Springs Rd, Dallas, Texas 75219 Phone: (214) 599-7020 | |
Aids Healthcare Foundation Type: Pharmacy Location: 7777 Forest Ln, Dallas, Texas 75230 Phone: (972) 383-1070 | |
Pearle Vision Type: Eyewear Supplier (Equipment, not the service) Location: 2130 S Buckner Blvd, Dallas, Texas 75227 Phone: (214) 381-1400 |